External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET‐thrombosis) in a large cohort of Chinese patients

Abstract

We validate the reproducibility of IPSET-thrombosis in Chinese ET patients and provide key clinical implications.

Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service

“…15 In the future, however, some authors already believe that the IPSET-thrombosis classification will be incorporated to stratify patients with ET. 8,9,16 The demographic characteristics, clinical and laboratory parameters of our sample of patients are similar to those described in the literature. 3 Hemorrhagic events were less prevalent than the thrombotic ones also in agreement with previous studies.…”

“…[17][18][19] Additionally, in agreement with other authors, we found a significant association between splenomegaly and venous thrombosis, and cardiovascular risk factors and a high WBC with arterial thrombosis. 1,7,8,10,16 Interestingly, age ≥ 60 years in our cohort of patients was not a significant risk factor for thrombosis. The lack of correlation between older age and thrombosis was also seen in other recent studies such as those of Lekovic et al 1 and Montanaro et al 20 The presence of JAK2 mutation was not significantly associated with thrombosis in our study, contrary to information well-established in the literature.…”

“…The lack of correlation between older age and thrombosis was also seen in other recent studies such as those of Lekovic et al 1 and Montanaro et al 20 The presence of JAK2 mutation was not significantly associated with thrombosis in our study, contrary to information well-established in the literature. 14,16,[20][21][22] We believe that our small sample size may explain why we found no correlation between thrombosis risk and the presence of JAK2 mutation.…”

IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort

“…Barbui et al 17 included patients from European countries and the United States as a validation cohort in this study. Fu et al 18 reported the results of their study, which validated the scoring system in a Chinese patient cohort. Conversely, Angona et al 21 failed to validate the system in a single-center setting in a Spanish patient cohort.…”

“…17 The IPSET-Thrombosis score was validated by an internal and external validation set. Most recently, Fu et al 18 V617F mutation frequency in Turkish patient cohorts compared to other patient populations, and they have also documented an increased risk of thrombosis in JAK2 V617F mutationepositive ET patients. To date, the reproducibility of the IPSET-Thrombosis score compared to the conventional scoring system has not been reported in a Turkish population.…”